TNGX stock touches 52-week low at $2.58 amid market challenges
In a challenging market environment, TNGX stock has reached a new 52-week low, with shares plummeting to $2.58. According to InvestingPro data, while the company maintains strong liquidity with a ...
Voyager Provides Update on SOD1 ALS Gene Therapy Program
Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs ...
Deutsche Bank sets Neurocrine stock with $138 price target
Deutsche Bank (ETR:DBKGn) began coverage on Neurocrine Biosciences (NASDAQ:NBIX) stock, assigning a Hold rating and setting a price target of $138. The bank's analyst noted that with a current market ...
Medscape9h
Underfunded, Underdiagnosed, and Misunderstood: What’s Next for Bipolar Disorder
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
Neurocrine initiated with a Hold at Deutsche Bank
Deutsche Bank initiated coverage of Neurocrine (NBIX) with a Hold rating and $138 price target Maximize Your Portfolio with Data Driven ...
Analysts Are Bullish on These Healthcare Stocks: Labcorp Holdings (LH), Neurocrine (NBIX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Labcorp Holdings (LH – Research Report) and ...
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $163.00 at Guggenheim
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy ...
Why Neurocrine Biosciences Stock Sank Today
Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences ...